nach oben

Erschienen in:

21.12.2015 | Case Report

Late Recurrence of Low-Risk Stage II Colorectal Cancer Shortly After Etanercept

verfasst von: Tony Ibrahim, Khalil Saleh, Viviane Track-smayra, Nelly Ziade, Dalia Sarraf, Charbel Yazbeck, Nadine Khalife, Fadi Nasr

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Excerpt

Tumor necrosis factor alpha (TNF alpha), as its name would indicate, is an immunomodulatory cytokine shown to have anti-tumor activity [1]. The use of TNF alpha inhibitors in rheumatologic diseases has grown substantially, but debate has emerged regarding the administration of these agents to patients known to have a history of solid malignancies in remission [2, 3]. We present here a case of systemic recurrence of low-risk colorectal cancer after the use of etanercept, a TNF alpha-sequestering agent. …

Roh MS, Wang L, Oyedeji C, et al. Human Kupffer cells are cytotoxic against human colon adenocarcinoma. Surgery. 1990;108(2):400–5.PubMed

Kopylov U, Vutcovici M, Kezouh A, Seidman E, Bitton A, Afif W. Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec claims database study. Inflamm Bowel Dis. 2015;21(8):1847–53.CrossRefPubMed

Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2015;74:1087.CrossRefPubMed

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon cancer Version 3.2015. 2015 October 5; National Comprehensive Cancer Network. [available at http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf].

Larmonier N, Cathelin D, Larmonier C, et al. The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. Exp Cell Res. 2007;313(11):2345–55.CrossRefPubMed

Heim ME, Siegmund R, Illiger HJ, et al. Tumor necrosis factor in advanced colorectal cancer: a phase II study. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie. 1990;13(6):444–7.PubMed

Schaadt M, Pfreundschuh M, Lorscheidt G, Peters KM, Steinmetz T, Diehl V. Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma. J Biol Response Mod. 1990;9(2):247–50.PubMed

Flores MB, Rocha GZ, Damas-Souza DM, et al. Obesity-induced increase in tumor necrosis factor-α leads to development of colon cancer in mice. Gastroenterology. 2012;143(3):741–53.CrossRefPubMed

van Grevenstein WM, Hofland LJ, van Rossen ME, van Koetsveld PM, Jeekel J, van Eijck CH. Inflammatory cytokines stimulate the adhesion of colon carcinoma cells to mesothelial monolayers. Dig Dis Sci. 2007;52(10):2775–83.CrossRefPubMed

10.

Stanilov N, Miteva L, Dobreva Z, Stanilova S. Colorectal cancer severity and survival in correlation with tumour necrosis factor-alpha. Biotechnol Biotechnol Equip. 2014;28(5):911–7.CrossRefPubMedPubMedCentral

Titel: Late Recurrence of Low-Risk Stage II Colorectal Cancer Shortly After Etanercept
verfasst von: Tony Ibrahim
Khalil Saleh
Viviane Track-smayra
Nelly Ziade
Dalia Sarraf
Charbel Yazbeck
Nadine Khalife
Fadi Nasr
Publikationsdatum: 21.12.2015
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 4/2016
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-015-9788-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Late Recurrence of Low-Risk Stage II Colorectal Cancer Shortly After Etanercept

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Diagnostic and Prognostic Value of miR-1287 in Colorectal Cancer

Prevalence of Helicobacter pylori Infection in Patients with Squamous Cell Carcinoma of the Oesophagus. A Descriptive Case Series Study

Small Bowel Gastrointestinal Stromal Tumor (GIST) Presenting with Liver Abscesses

Helicobacter pylori Peptidyl Prolyl Isomerase Expression Is Associated with the Severity of Gastritis

Synchronous Adenocarcinoma and Lymphoma of the Gallbladder: A Case Report

Report of two Cases with Metastasis in Lymph NodesAlong the Posterior Leaf of the Bursa Omentalis at the Area of the Pancreatic Body, an Area not Routinely Examined in Standard Gastrectomy Plus Bursectomy for Advanced Gastric Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie